Literature DB >> 3766757

Clearance of human platelet factor 4 by liver and kidney: its alteration by heparin.

B Rucinski, L C Knight, S Niewiarowski.   

Abstract

Human 125I-labeled platelet factor 4 (PF4) injected into rabbits showed a biphasic exponential pattern of disappearance from the circulation [half-life of the fast components was 0.75 min, that of the slow components was 20 min] that was not affected by a 1,000-fold excess of unlabeled PF4. Heparin resulted in a single-compartment disappearance of 125I-labeled PF4 (half-life = 25-40 min). Five minutes after injection of 125I-labeled PF4 greater than 40% radioactivity had accumulated in the liver and 4% in the kidney. At that time, accumulation of 125I-labeled beta-thromboglobulin (beta-TG) in the organs was low, approximately 4% in the kidneys and less than 3.0% in the liver. Nuclear imaging studies revealed rapid clearance of 131I-labeled PF4 from blood and its predominant accumulation in the liver. The half-lives of 131I-labeled PF4 radioactivity in liver and kidney were 96 and 252 min, fitting a single-compartment model. 131I-labeled beta-TG accumulated predominantly in the kidney. The half-lives of 131I-labeled beta-TG radioactivity in the kidney and in the liver were 84 and 414 min. Simultaneous or subsequent injection of heparin did not affect the distribution of 131I-labeled beta-TG but caused partial loss of 131I-labeled PF4 radioactivity from the liver and accelerated its appearance in the urinary bladder. Injection of heparin resulted in a 100-fold increase of excretion in the urine of 125I-labeled Pf4 precipitable by 10% trichloroacetic acid.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3766757     DOI: 10.1152/ajpheart.1986.251.4.H800

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  6 in total

1.  The role of liver and kidney on the pharmacokinetics of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in rats.

Authors:  R J Bauer; K Der; N Ottah-Ihejeto; J Barrientos; A H Kung
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

2.  The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21).

Authors:  Sanjay Khandelwal; Grace M Lee; C Garren Hester; Mortimer Poncz; Steven E McKenzie; Bruce S Sachais; Lubica Rauova; Garnett Kelsoe; Douglas B Cines; Michael Frank; Gowthami M Arepally
Journal:  Blood       Date:  2016-07-13       Impact factor: 22.113

3.  A monoclonal antibody against rat platelets. I. Tissue distribution in vitro and in vivo.

Authors:  W M Bagchus; M F Jeunink; J Rozing; J D Elema
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

4.  Inhibition of human megakaryocytopoiesis in vitro by platelet factor 4 (PF4) and a synthetic COOH-terminal PF4 peptide.

Authors:  A M Gewirtz; B Calabretta; B Rucinski; S Niewiarowski; W Y Xu
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

5.  Molecular imaging of bacterial infections in vivo: the discrimination of infection from inflammation.

Authors:  Heather Eggleston; Peter Panizzi
Journal:  Informatics (MDPI)       Date:  2014-05-30

Review 6.  Chemokine receptors: multifaceted therapeutic targets.

Authors:  Amanda E I Proudfoot
Journal:  Nat Rev Immunol       Date:  2002-02       Impact factor: 53.106

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.